{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:39:11Z","timestamp":1781203151780,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Pathology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.carpath.2019.107150","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T02:11:00Z","timestamp":1566958260000},"page":"107150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy"],"prefix":"10.1016","volume":"43","author":[{"given":"Chengzhi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carpath.2019.107150_bb0005","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.jacc.2019.01.061","article-title":"Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy","volume":"73","author":"Maron","year":"2019","journal-title":"JACC Review Topic of the Week J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2019.107150_bb0010","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jacc.2010.05.010","article-title":"Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy","volume":"56","author":"O'Hanlon","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2019.107150_bb0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jacc.2009.12.074","article-title":"Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease","volume":"56","author":"Azevedo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2019.107150_bb0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cardfail.2016.03.010","article-title":"Serum matrix metalloproteinases as quantitative biomarkers for myocardial fibrosis and sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy","volume":"22","author":"Munch","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.carpath.2019.107150_bb0025","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1536\/ihj.18-598","article-title":"Predictive values of apelin for myocardial fibrosis in hypertrophic cardiomyopathy","volume":"60","author":"Zhou","year":"2019","journal-title":"Int Heart J"},{"key":"10.1016\/j.carpath.2019.107150_bb0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2010.05.007","article-title":"Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy","volume":"56","author":"Bruder","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2019.107150_bb0035","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.carpath.2019.107150_bb0040","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2013.05.077","article-title":"T1 mapping for diffuse myocardial fibrosis: a key biomarker in cardiac disease?","volume":"62","author":"Moon","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2019.107150_bb0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tcm.2014.09.004","article-title":"The 20 advances that have defined contemporary hypertrophic cardiomyopathy","volume":"25","author":"Maron","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.carpath.2019.107150_bb0050","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/FJC.0b013e31821823d9","article-title":"Vos MA, van Rijen HV. Biomarkers of myocardial fibrosis","volume":"57","author":"de Jong","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.carpath.2019.107150_bb0055","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.jacc.2015.04.026","article-title":"Circulating biomarkers of myocardial fibrosis","volume":"65","author":"Lopez","year":"2015","journal-title":"The Need for a Reappraisal J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2019.107150_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/eurheartj\/ehn538","article-title":"Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis","volume":"30","author":"Cambronero","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carpath.2019.107150_bb0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tcm.2016.07.005","article-title":"Biomarkers in cardiovascular disease: statistical assessment and section on key novel heart failure biomarkers","volume":"27","author":"Dhingra","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.carpath.2019.107150_bb0070","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/01.CIR.0000090687.97972.10","article-title":"Myocardial collagen turnover in hypertrophic cardiomyopathy","volume":"108","author":"Lombardi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.carpath.2019.107150_bb0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa1002659","article-title":"Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy","volume":"363","author":"Ho","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carpath.2019.107150_bb0080","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1152\/physrev.00012.2007","article-title":"Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function","volume":"87","author":"Spinale","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.carpath.2019.107150_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cca.2014.06.028","article-title":"Biomarkers of the extracellular matrix and of collagen fragments","volume":"443","author":"Chalikias","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.carpath.2019.107150_bb0090","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carpath.2019.107150_bb0095","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.ahj.2006.04.022","article-title":"Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure","volume":"152","author":"Gerlach","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.carpath.2019.107150_bb0100","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.clinbiochem.2012.03.035","article-title":"Measurement of C-terminal telopeptide of type I collagen (CTX) in serum","volume":"45","author":"Chubb","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.carpath.2019.107150_bb0105","article-title":"Outcomes of an extended morrow procedure without a concomitant mitral valve procedure for hypertrophic obstructive cardiomyopathy","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.carpath.2019.107150_bb0110","first-page":"473","article-title":"American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy","volume":"24","author":"Nagueh","year":"2011","journal-title":"Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography J Am Soc Echocardiogr"},{"key":"10.1016\/j.carpath.2019.107150_bb0115","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/13547500903098293","article-title":"Serum procollagen type III is associated with elevated right-sided filling pressures in stable outpatients with congestive heart failure","volume":"14","author":"Biolo","year":"2009","journal-title":"Biomarkers"},{"key":"10.1016\/j.carpath.2019.107150_bb0120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carpath.2019.107150_bb0125","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jacc.2008.08.064","article-title":"Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy","volume":"53","author":"Rudolph","year":"2009","journal-title":"relation to remodeling J Am Coll Cardiol"},{"key":"10.1016\/j.carpath.2019.107150_bb0130","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1253\/circj.CJ-15-1269","article-title":"Characterization of compacted myocardial abnormalities by cardiac magnetic resonance with native T1 mapping in left ventricular non-compaction patients\u2014a comparison with late gadolinium enhancement","volume":"80","author":"Zhou","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.carpath.2019.107150_bb0135","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.hlc.2018.07.019","article-title":"Sudden cardiac death and ventricular arrhythmias in hypertrophic cardiomyopathy","volume":"28","author":"Moore","year":"2019","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.carpath.2019.107150_bb0140","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/01.CIR.101.14.1729","article-title":"Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease","volume":"101","author":"Querejeta","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.carpath.2019.107150_bb0145","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00011-016-0977-3","article-title":"Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy","volume":"65","author":"Rubis","year":"2016","journal-title":"Inflamm Res"},{"key":"10.1016\/j.carpath.2019.107150_bb0150","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/01.CIR.0000140973.60992.9A","article-title":"Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis","volume":"110","author":"Querejeta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.carpath.2019.107150_bb0155","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.109.912774","article-title":"Circulating biomarkers of collagen metabolism in cardiac diseases","volume":"121","author":"Lopez","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.carpath.2019.107150_bb0160","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1161\/CIRCULATIONAHA.106.638569","article-title":"Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction","volume":"115","author":"Martos","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.carpath.2019.107150_bb0165","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/eurjhf\/hfs179","article-title":"Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure","volume":"15","author":"Kaye","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.carpath.2019.107150_bb0170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1172\/JCI200214677","article-title":"The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model","volume":"109","author":"Semsarian","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.carpath.2019.107150_bb0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejheart.2005.07.012","article-title":"Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy","volume":"8","author":"Westermann","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.carpath.2019.107150_bb0180","first-page":"180","article-title":"Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers","volume":"3","author":"Ho","year":"2015","journal-title":"a pilot randomized trial to modify disease expression JACC Heart Fail"},{"key":"10.1016\/j.carpath.2019.107150_bb0185","first-page":"77","article-title":"Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects","volume":"22","author":"Risteli","year":"1995","journal-title":"J Hepatol"}],"container-title":["Cardiovascular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054880719301693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054880719301693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:45:00Z","timestamp":1760960700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054880719301693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":37,"alternative-id":["S1054880719301693"],"URL":"https:\/\/doi.org\/10.1016\/j.carpath.2019.107150","relation":{},"ISSN":["1054-8807"],"issn-type":[{"value":"1054-8807","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carpath.2019.107150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107150"}}